CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A
ACTIMMUNE (S) Prior Authorization Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - South Carolina policy alerts
Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
This policy governs prior authorization for Actimmune injection under the South Carolina PDP Basic Medicare Part D plan. Coverage applies to members seeking treatment for chronic granulomatous disease or severe malignant osteopetrosis.
Policy Summary
PayerBlue Cross Blue Shield - South Carolina
PolicyACTIMMUNE (S) Prior Authorization Criteria
Policy CodePolicy N/A
Change TypeNo material change
Effective DateOct 1, 2026
Next Review DateN/A
Key ActionSubmit documentation confirming chronic granulomatous disease or severe malignant osteopetrosis.
No material clinical or coverage changes in this revision.
2Covered diagnoses
12 monthsCoverage duration
Not requiredPrerequisite Part D drug
Part DBenefit category
Coverage Criteria
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
Actimmune initial and continuation therapy criteria
Actimmune is covered when the patient meets one eligible diagnosis.
Eligible diagnosis
Chronic granulomatous disease: Diagnosis of chronic granulomatous disease (CGD).
Severe malignant osteopetrosis: Diagnosis of severe malignant osteopetrosis (SMO).
Adempas initial and continuation therapy criteria
Adempas is covered when the applicable indication-specific criteria are met.
Initial therapy
PAH: Diagnosis of symptomatic pulmonary arterial hypertension; the diagnosis was confirmed by right-heart catheterization or the patient is currently receiving PAH therapy.
CTEPH: Diagnosis of symptomatic inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension, or the patient is currently receiving therapy for CTEPH.
Continuation therapy: Patient demonstrates positive clinical response to therapy.
Afinitor and Afinitor Disperz criteria
Everolimus products are covered when the applicable indication and age criteria are met.
Afinitor indications
SEGA associated with tuberous sclerosis complex requiring therapeutic intervention; patient is at least 1 year old.
Advanced renal cell carcinoma with trial and failure, contraindication, or intolerance to SUTENT or NEXAVAR.
Progressive, unresectable, locally advanced, or metastatic pNET.
Renal angiomyolipoma associated with TSC.
Advanced hormone receptor-positive, HER2-negative breast cancer with trial and failure, contraindication, or intolerance to FEMARA or ARIMIDEX.
Aimovig initial and continuation criteria
Aimovig is covered for initial preventive migraine treatment and reauthorization when benefit is documented.
Initial migraine indication
Episodic migraine with at least 4 migraine days per month.>= 4 migraine days/month
Chronic migraine with medication-overuse headache considered and potentially offending medication discontinued, and at least 8 migraine days per month.>= 8 migraine days/month
Age: Patient is at least 18 years old.
Continuation: Positive response is documented; acute migraine medication use has decreased; the drug is not used with another CGRP inhibitor; and chronic migraine patients continue medication-overuse-headache monitoring.
Akeega criteria
All of the following criteria must be met.
Akeega: Diagnosis of metastatic prostate cancer with a deleterious or suspected deleterious BRCA mutation; used with prednisone and a GnRH agent.
Alecensa and Alunbrig criteria
All of the following criteria must be met for the requested product.
Alecensa or Alunbrig: Diagnosis of non-small cell lung cancer (NSCLC).
Prolastin-C initial and continuation criteria
Prolastin-C is covered when all alpha-1 antitrypsin deficiency criteria are met.
Initial therapy: Congenital AAT deficiency; emphysema; continued conventional emphysema treatment; qualifying PiZZ, PiZ(null), Pi(null)(null), or other qualifying genotype; and pretreatment serum AAT below 11 µM/L.< 11 µM/L
Continuation therapy: Positive clinical response is documented and conventional emphysema treatment continues.
Dalfampridine criteria
Dalfampridine ER is covered for MS-related walking impairment when the applicable initial or continuation criteria are met.
Initial therapy: Diagnosis of multiple sclerosis; physician-confirmed difficulty walking; and EDSS of 7 or less, or the patient is not restricted to wheelchair use when EDSS is not measured.EDSS <= 7 or not restricted to wheelchair
Prescribed by or in consultation with a neurologist.
Continuation therapy: Physician confirms walking improved with therapy, and EDSS remains 7 or less or the patient is not restricted to wheelchair use when EDSS is not measured.
Arformoterol, Arikayce, Augtyro, Avmapki Fakzynja Co-pack, Avtozma, and Ayvakit criteria
Coverage requires the applicable product-specific indication criteria.
Arformoterol Tartrate: Diagnosis of COPD and use for maintenance treatment of bronchoconstriction, including chronic bronchitis and emphysema.
Arikayce: MAC lung disease; use in combination with antibacterial therapy; and failure to achieve at least two negative sputum cultures after at least 6 consecutive months of multidrug background therapy.At least 2 negative cultures after >= 6 months
Augtyro
Locally advanced or metastatic NSCLC with a ROS1 rearrangement-positive tumor.
Locally advanced, metastatic, or unresectable NTRK fusion solid tumor that progressed after prior treatment or has no satisfactory alternative treatment.
Balversa, Benlysta, Besremi, and Bosulif criteria
Coverage requires the applicable disease, biomarker, treatment-history, and combination criteria.
Balversa: Locally advanced or metastatic urothelial carcinoma; susceptible FGFR3 alteration confirmed by FDA-approved or CLIA-approved testing; progression after at least one prior systemic therapy; and prior PD-1/PD-L1 therapy or documented inability to receive it.
Benlysta
Active SLE; ANA titer at least 1:80 or anti-dsDNA at least 30 IU/mL; current standard-of-care treatment; age at least 5 years.ANA >= 1:80 or anti-dsDNA >= 30 IU/mL
Active lupus nephritis; corticosteroid-based treatment with mycophenolate or cyclophosphamide; age at least 5 years.
Besremi: Polycythemia vera; qualifying hemoglobin or hematocrit; JAK2 V617F/JAK2 exon 12 mutation or subnormal erythropoietin; and prerequisite therapy for high-risk disease.
Braftovi, Briviact, Bronchitol, and Brukinsa criteria
Coverage requires the applicable indication-specific criteria.
Braftovi
Unresectable or metastatic BRAF V600E/V600K-mutant melanoma with Mektovi.
Advanced or metastatic BRAF V600E-mutant colorectal cancer with Erbitux and prior therapy or fluorouracil-based chemotherapy.
Metastatic BRAF V600E-mutant NSCLC with Mektovi.
Briviact: Partial-onset seizures and age at least 1 month.
Bronchitol: Cystic fibrosis and passed Bronchitol Tolerance Test.
Cablivi through Cholbam criteria
Coverage requires the applicable disease and treatment criteria.
Cablivi: aTTP; first dose administered by a healthcare provider as an IV bolus; immunosuppressive therapy; and ongoing plasma exchange or completed plasma exchange with fewer than 59 days elapsed.
Cabometyx
RCC.
HCC with Nexavar trial and failure, contraindication, or intolerance.
DTC progressed after VEGFR-targeted therapy and refractory or ineligible for radioactive iodine; age at least 12 years.
Well-differentiated, unresectable, locally advanced, or metastatic pNET/epNET previously treated.
Tadalafil through Cosentyx criteria
Coverage requires the applicable indication-specific criteria.
Tadalafil: No concurrent nitrate use and contraindication or intolerance to an alpha-blocker or 5-alpha reductase inhibitor.
Ciclopirox: No lunula or matrix involvement; confirmed fingernail or toenail onychomycosis; mild-to-moderate target-toenail disease when applicable; and oral terbinafine trial and failure, contraindication, or intolerance.
Cinryze: Age at least 6 years; HAE prophylaxis indication; specialist prescribing or consultation; qualifying HAE laboratory or genetic/family-history confirmation; and no combination with another approved HAE prophylaxis treatment.
Cobenfy: Intolerance to two listed oral generic formulary atypical antipsychotics.2 agents
Danziten through Dulera criteria
Coverage requires the applicable disease, treatment-history, laboratory, and response criteria.
Danziten: Philadelphia chromosome-positive CML.
Pyrimethamine
Active treatment, secondary prophylaxis, or congenital toxoplasmosis treatment.
Primary toxoplasmosis prophylaxis with TMP-SMX intolerance and failed desensitization/rechallenge or prior life-threatening TMP-SMX reaction.
Daurismo: Newly diagnosed AML used with low-dose cytarabine and either age at least 75 years or comorbidities precluding intensive induction.
Deferasirox
Dupixent through Enbrel criteria
Coverage requires the requested product's indication-specific initial criteria and, for reauthorization, documented benefit.
Dupixent
Eosinophilic asthma or corticosteroid-dependent asthma meeting severity, controller-therapy, and age requirements.
CRSwNP with inadequate intranasal corticosteroid response and combination therapy.
EoE with symptoms, at least 15 eosinophils per high-power field, weight at least 15 kg, and required treatment trial.
Moderate-to-severe atopic dermatitis meeting BSA or SCORAD severity and topical-treatment criteria.
COPD with type 2 inflammation, maximally tolerated inhaled therapy, and exacerbation or hospitalization criteria.
Pirfenidone through Itraconazole coverage criteria
Coverage requires the applicable initial indication criteria; continuation is approved when prior therapy and any required response criteria are documented.
Pirfenidone: IPF is documented by exclusion of other known ILD causes and qualifying HRCT or HRCT-plus-biopsy findings; initial prescribing is by or in consultation with a pulmonologist.
Eucrisa: Mild-to-moderate atopic dermatitis and trial/failure, contraindication, or intolerance to one prescription-strength topical corticosteroid, unless the affected area is sensitive.
Evrysdi: SMA type I, II, or III with qualifying 5q abnormality and at least 2 SMN2 copies; qualifying baseline motor assessment; applicable ventilation status; no concomitant chronic SMN-modifying therapy; and applicable gene-therapy history.>= 2 SMN2 copies
Fabrazyme:
Coverage exclusions and combination-use restrictions apply as follows: tadalafil 2.5 mg and 5 mg are not covered with concurrent nitrate use; Cinryze must not be used with another approved prophylactic treatment for hereditary angioedema; Evrysdi is not covered with concomitant chronic SMN-modifying therapy, such as Spinraza; Fabrazyme is not covered with other drugs used for Fabry disease; and icatibant is not covered with another approved treatment for acute HAE attacks.
Fingolimod hydrochloride and glatiramer acetate must not be used with another disease-modifying therapy for multiple sclerosis. Pyrimethamine for malaria treatment or prophylaxis is not authorized and will not be approved. Metyrosine will not be covered when used to control essential hypertension.
Clinical thresholds and authorization values
Migraine frequencyEpisodic migraine: >= 4 migraine days per month; chronic migraine: >= 8 migraine days per month
Pretreatment serum AAT< 11 µM/L, corresponding to < 80 mg/dL if measured by radial immunodiffusion
Dalfampridine functional statusEDSS <= 7, or patient is not restricted to using a wheelchair when EDSS is not measured
Arikayce sputum culturesAt least two negative sputum cultures after a minimum of 6 consecutive months of multidrug background regimen therapy
For the products addressed in this section, the policy lists no separate product-specific exclusion criteria; the exclusion-criteria field is identified as not applicable. This does not waive the coverage requirements. Requests must still satisfy the applicable diagnosis, severity, prior-treatment, prescriber, combination-therapy, and continuation criteria.
Coverage may be denied when the applicable clinical requirements are not met, including required prerequisite therapy, prescriber restrictions, or documented positive clinical response for reauthorization. Providers should submit supporting records that establish each applicable criterion rather than relying solely on the absence of a separately listed exclusion.
Initial Therapy Criteria
Initial authorization and early-product initial therapy criteria
Initial authorization requires the applicable product indication and clinical criteria.
Covered initial indications
Actimmune: CGD or SMO.
Adempas: qualifying PAH or CTEPH.
Afinitor or Afinitor Disperz: applicable everolimus or TSC-related indication and age criteria.
Aimovig: episodic migraine with at least 4 migraine days/month or chronic migraine with at least 8 migraine days/month; age at least 18 years.
Akeega: metastatic BRCA-mutated prostate cancer with prednisone and GnRH therapy.
Alecensa or Alunbrig: NSCLC.
Prolastin-C: congenital AAT deficiency with emphysema, conventional treatment, qualifying genotype, and serum AAT below 11 µM/L.
Dalfampridine ER: MS with walking difficulty and EDSS at most 7 or no wheelchair restriction.
Avtozma through Brukinsa initial therapy criteria
Initial authorization requires the applicable indication-specific criteria.
Avtozma
RA, GCA, SJIA, PJIA, or SSc-ILD meeting the applicable diagnosis, prerequisite, specialist, and disease criteria.
Balversa: Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alteration, prior systemic therapy, and prior PD-1/PD-L1 therapy or inability to receive it.
Benlysta
Active SLE with qualifying autoantibodies, standard-of-care therapy, and age at least 5 years.
Active lupus nephritis with corticosteroid-based treatment plus mycophenolate or cyclophosphamide, and age at least 5 years.
Cablivi through Cosentyx initial therapy criteria
Initial authorization requires the applicable disease, severity, biomarker, treatment-history, and specialist criteria.
Cablivi: aTTP; provider-administered first IV bolus; immunosuppressive therapy; and ongoing or recently completed plasma exchange.
Cabometyx
RCC.
HCC after Nexavar failure, contraindication, or intolerance.
DTC after VEGFR therapy and radioactive-iodine refractory/ineligible disease; age at least 12 years.
Previously treated well-differentiated unresectable, locally advanced, or metastatic pNET/epNET.
Calquence
Danziten through Enbrel initial therapy criteria
Initial therapy requires the applicable diagnosis-specific pathway; reauthorization requires the stated response or continuation criteria.
Danziten: Philadelphia chromosome-positive CML.
Pyrimethamine
Qualifying toxoplasmosis treatment or prophylaxis indication.
Daurismo: Newly diagnosed AML with low-dose cytarabine and age/comorbidity eligibility.
Deferasirox
Transfusional iron overload with ferritin over 1,000 mcg/L and at least 100 mL/kg RBC transfusions.
Initial authorization requires the applicable diagnosis, treatment history, laboratory findings, and specialist requirements.
Actimmune: CGD or SMO.
Pirfenidone: IPF documented by exclusion of other ILD causes and qualifying HRCT or biopsy findings; pulmonologist involvement.
Eucrisa: Mild-to-moderate AD with prescription-strength topical corticosteroid failure, contraindication, or intolerance unless the area is sensitive.
Evrysdi: SMA type I, II, or III with qualifying genetics, at least 2 SMN2 copies, baseline motor assessment, ventilation eligibility, no chronic SMN-modifying therapy, and applicable gene-therapy history; neurologist involvement.
Hernexeos through Itraconazole initial criteria
Initial authorization requires the applicable disease, biomarker, treatment-history, and combination criteria.
Hernexeos: Unresectable or metastatic non-squamous NSCLC with an activating HER2 mutation confirmed by approved testing.
Humira
One covered indication—RA, PJIA, PsA, plaque psoriasis, AS, CD, uveitis, UC, or HS—meeting its disease-severity and prerequisite-treatment criteria.
Hyrnuo: Locally advanced or metastatic non-squamous NSCLC with activating HER2 mutation and prior systemic therapy.
Inbrija: Parkinson disease with intermittent OFF episodes, current carbidopa/levodopa, and failure, contraindication, or intolerance to two specified medication classes; neurologist involvement.
Increlex
Continuation and Reauthorization Criteria
General continuation, Adempas, Aimovig, and Dalfampridine continuation criteria
Continuation is approved when prior therapy is documented and the applicable response requirements are met.
General continuation: The requested drug was previously authorized and continuation of therapy is documented.
Adempas: Positive clinical response is documented.
Aimovig: Positive response, reduced acute migraine medication use, no concurrent CGRP inhibitor, and medication-overuse-headache monitoring when applicable.
Dalfampridine ER: Walking improved with therapy and EDSS remains at most 7 or wheelchair restriction remains absent when EDSS is not measured.
Avtozma through Cholbam continuation criteria
Continuation is approved when prior therapy is documented and any product-specific response requirement is met.
Prior therapy continuation: Previously authorized therapy is continued for Avtozma, Augtyro, Avmapki Fakzynja Co-pack, Ayvakit, Balversa, Brukinsa, Cabometyx, Calquence, or Caplyta.
Avtozma: Positive clinical response appropriate to RA, PJIA, SJIA, GCA, or SSc-ILD is documented.
Benlysta: Positive clinical response is documented.
Bronchitol: Positive clinical response is documented.
Cayston: Benefit is documented, including improvement in or decreased pulmonary exacerbations.
Cinryze through Dulera continuation criteria
Continuation is approved when prior therapy is documented and the stated response or disease-control criteria remain satisfied.
Cinryze: Positive clinical response and no combination with another approved HAE prophylaxis treatment.
Cometriq, Cobenfy, Danziten, Daurismo, or Diacomit: Continuation of prior therapy is documented.
Cosentyx: Positive diagnosis-specific clinical response from baseline is documented.
Doptelet for ITP: Platelet count increases to a level sufficient to avoid clinically important bleeding.
Dulera:
Dupixent through Enbrel continuation criteria
Reauthorization requires positive clinical response and continued indication-specific therapy where applicable.
Dupixent: Positive clinical response is documented; CRSwNP combination therapy and COPD inhaled therapy continue when required.
Ebglyss: BSA involvement or SCORAD is reduced from baseline.
Emgality: Positive response, reduced acute migraine medication use when applicable, continued medication-overuse-headache monitoring for chronic migraine, and no prohibited concurrent CGRP therapy.
Empaveli: Positive clinical response; C3G/primary IC-MPGN background ACE inhibitor, ARB, or SGLT2 therapy continues, and primary IC-MPGN remains without kidney transplant.
Fintepla through Itovebi continuation criteria
Continuation is approved when prior therapy is documented and product-specific response or safety criteria remain satisfied.
Pirfenidone or Eucrisa: Positive clinical response is documented.
Evrysdi: Positive response; no concomitant chronic SMN-modifying therapy; and applicable gene-therapy history or inadequate-response documentation.
Fabrazyme: Positive response and no combination with other Fabry disease drugs.
Fintepla, Firmagon, Imatinib, Gomekli, Hernexeos, Hyrnuo, Inlyta, Inqovi, or Inrebic: Continuation of prior therapy is documented; product-specific indication remains supported.
Icatibant:
Actimmune reauthorization criteria
Actimmune reauthorization requires positive clinical response from baseline.
Condition-specific response
For RA or PJIA, active joint count is reduced or symptoms improve from baseline.
For PsA, active joint count or symptoms improve, or BSA involvement is reduced from baseline.
For plaque psoriasis, BSA involvement is reduced or pruritus/inflammation improves from baseline.
For AS, disease activity, laboratory values, function, axial status, or active joint count improves from baseline.
Prior Authorization and Provider Requirements
Prior Authorization
Prior Authorization Required
Prior authorization is required for Actimmune and everolimus products. For Actimmune, approve medically accepted indications when the patient has a documented diagnosis of chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO). For everolimus tablets, coverage applies to medically accepted indications subject to the product-specific requirements below.
Actimmune INJ 100MCG/0.5ML: Coverage duration is 12 months; continuation of prior therapy may be approved.
Everolimus tablets 2.5 mg, 5 mg, 7.5 mg, and 10 mg: Coverage duration is 12 months for all covered indications; continuation of prior therapy may be approved.
No age or prescriber restriction is specified for Actimmune. Everolimus for SEGA associated with TSC requires the patient to be at least 1 year of age.
Step Therapy
Prerequisite Therapy and Continuation
Everolimus requires use of a prerequisite Part D drug. Document the applicable prerequisite treatment and outcome before requesting authorization.
For advanced renal cell carcinoma, document trial and failure, contraindication, or intolerance to SUTENT (sunitinib) or NEXAVAR (sorafenib).
For advanced hormone receptor-positive, HER2-negative breast cancer, document trial and failure, contraindication, or intolerance to FEMARA (letrozole) or ARIMIDEX (anastrozole).
Actimmune does not require use of a prerequisite Part D drug.
Documentation Required
Required Clinical Documentation
Submit medical records supporting the diagnosis, disease status, treatment history, age when applicable, and requested indication. Documentation must establish the product-specific clinical criteria and support continuation when the patient is already receiving therapy.
Actimmune: Document CGD or SMO diagnosis and, for continuation, prior Actimmune therapy.
Everolimus for SEGA: Document TSC-associated SEGA requiring therapeutic intervention and patient age of at least 1 year.
Everolimus for renal cell carcinoma: Document advanced disease and the required SUTENT or NEXAVAR treatment history or contraindication/intolerance.
Everolimus for progressive pNET: Document unresectable, locally advanced, or metastatic disease.
Everolimus for renal angiomyolipoma: Document renal angiomyolipoma associated with TSC.
Everolimus for breast cancer: Document advanced hormone receptor-positive, HER2-negative disease and the required letrozole or anastrozole treatment history or contraindication/intolerance.
Everolimus for GI or lung NET: Document progressive, well-differentiated, non-functional disease that is unresectable, locally advanced, or metastatic.
Denial Risk
Denial Risks and Unmet Criteria
Authorization may be denied when the requested use is not a medically accepted indication, the required diagnosis or disease characteristics are not established, prerequisite therapy requirements are unmet, or supporting records are insufficient. Continuation requests should include evidence of prior therapy.
Everolimus requests may be denied when the indication-specific diagnosis, progression, disease extent, TSC association, biomarker status, or required prior treatment is not documented.
Actimmune requests may be denied when CGD or SMO is not documented.
Everolimus requests may be denied when the patient does not meet the applicable age requirement for SEGA or when continuation of prior therapy is not established.
Missing, incomplete, or conflicting clinical documentation may prevent approval.
Denial Risk
Pyrimethamine Exclusion and Requirements
Pyrimethamine is covered for specified toxoplasmosis uses when the applicable clinical requirements are met. Malaria treatment and prophylaxis are excluded from authorization.
Toxoplasmosis: Coverage may be authorized for active treatment, secondary prophylaxis, or treatment of congenital toxoplasmosis.
Primary prophylaxis: Document intolerance to prior TMP-SMX and either failed desensitization/rechallenge or a prior life-threatening TMP-SMX reaction, such as toxic epidermal necrolysis or Stevens-Johnson syndrome.
Prescriber: Toxoplasmosis therapy must be prescribed by or in consultation with an infectious disease specialist.
Malaria exclusion: Requests for pyrimethamine treatment or prophylaxis of malaria will not be approved. The policy notes that this use is not recommended by the CDC.
Note
Provider Action Summary
This section summarizes provider actions for the specialty-drug prior authorization excerpt effective October 1, 2026. Submit the diagnosis, indication-specific clinical evidence, prerequisite treatment history when required, and continuation information through the applicable authorization process.
Actimmune: CGD or SMO diagnosis; 12-month coverage; no prerequisite Part D drug.
Everolimus: product-specific indication criteria, required prerequisite therapy for applicable indications, and 12-month coverage.
Pyrimethamine: toxoplasmosis criteria and infectious disease specialist involvement; malaria use is not covered.
Formulary reference for the everolimus entry: ID 26220, Version 18, effective 10/01/2026.
Prerequisite and Step-Therapy Requirements
Drug
Step-therapy requirement
Afinitor
For advanced renal cell carcinoma, trial and failure, contraindication, or intolerance to SUTENT (sunitinib) or NEXAVAR (sorafenib). For advanced hormone receptor-positive, HER2-negative breast cancer, trial and failure, contraindication, or intolerance to FEMARA (letrozole) or ARIMIDEX (anastrozole).
Avtozma
For rheumatoid arthritis or polyarticular juvenile idiopathic arthritis, trial and failure, contraindication, or intolerance to two specified agents, or attestation that a trial may be inappropriate. For systemic juvenile idiopathic arthritis, trial an NSAID such as ibuprofen or naproxen for at least 1 month at the maximally tolerated dose.
Balversa
Use of a prerequisite Part D drug is required.
Besremi
Use of a prerequisite Part D drug is required; high-risk polycythemia vera specifically requires a trial of prerequisite therapy.
Braftovi
Use of a prerequisite Part D drug is required. Use with Mektovi (binimetinib) for melanoma or metastatic NSCLC, or with Erbitux (cetuximab) for colorectal cancer.
Brukinsa
Use of a prerequisite Part D drug is required. Indication-specific prior therapy includes at least one prior therapy for MCL, at least one prior anti-CD20-based regimen for MZL, Calquence contraindication or intolerance for CLL/SLL, and at least two prior systemic therapy lines plus Gazyva for follicular lymphoma.
Cabometyx
Use of a prerequisite Part D drug is required. Depending on indication, prior therapy may include Nexavar failure, contraindication, or intolerance; prior VEGFR-targeted therapy; or previous treatment such as octreotide, lanreotide, or chemotherapy.
Calquence
Use of a prerequisite Part D drug is required. Previously untreated MCL requires bendamustine and rituximab when the patient is ineligible for autologous HSCT; alternatively, at least one prior MCL therapy is required.
Afinitor, Avtozma, Balversa, Besremi, Braftovi, Brukinsa, Cabometyx, and Calquence
Prerequisite Part D therapy is required unless the applicable indication-specific exception or continuation pathway applies.
Drug
Step-therapy requirement
Cabometyx
Use of a prerequisite Part D drug is required.
Calquence
Use of a prerequisite Part D drug is required. Previously untreated MCL requires bendamustine and rituximab when the patient is ineligible for autologous HSCT; alternatively, at least one prior MCL therapy is required.
Caplyta
Use of a prerequisite Part D drug is required. Trials include two generic formulary atypical antipsychotics for schizophrenia; quetiapine or olanzapine for bipolar depression; and aripiprazole plus quetiapine immediate-release or extended-release for adjunctive MDD treatment.
Tadalafil
Use of a prerequisite Part D drug consisting of an alpha-blocker or 5-alpha reductase inhibitor for which the patient has a contraindication or intolerance.
Ciclopirox
Oral terbinafine is required before ciclopirox: minimum 6-week trial and failure, contraindication, or intolerance for fingernail disease and minimum 12-week trial and failure, contraindication, or intolerance for toenail disease.
Cobenfy
Require intolerance to two oral generic formulary atypical antipsychotics, such as aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.
Copiktra
Require trial and failure, contraindication, or intolerance to at least two prior CLL/SLL therapies, such as chlorambucil, obinutuzumab, ofatumumab, bendamustine, ibrutinib, or rituximab.
Cosentyx — plaque psoriasis
Require at least a 4-week trial and failure, contraindication, or intolerance to one topical therapy, such as a corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor.
Cosentyx — ankylosing spondylitis
Require at least a 1-month trial and failure, contraindication, or intolerance to one NSAID at the maximally tolerated dose.
Cosentyx — nr-axSpA or ERA
Require at least a 1-month trial and failure, contraindication, or intolerance to two NSAIDs at maximally tolerated doses.
Drug
Step-therapy requirement
Metyrosine
Before metyrosine, use alpha-adrenergic and beta-adrenergic blocker therapy. For preoperative preparation, both therapies must have been tried and failed, contraindicated, or not tolerated; for treatment, normotension must not have been achieved after these therapies.
Doptelet
For initial ITP therapy, trial and failure, contraindication, or intolerance to at least one of corticosteroids, immunoglobulins, or splenectomy is required.
Dulera
Breo Ellipta is the prerequisite Part D therapy, subject to exceptions for safety concerns, age-related nonindication, or intolerance.
Dupixent
Use the applicable prerequisite therapy by indication: asthma controller therapy; intranasal corticosteroid for CRSwNP; proton pump inhibitor or topical esophageal corticosteroid for EoE; topical therapy for atopic dermatitis; maximally tolerated inhaled therapy for COPD; or H1 antihistamine therapy for CSU unless contraindicated.
Ebglyss
Trial and failure, contraindication, or intolerance to a medium- or higher-potency topical corticosteroid is required: minimum 30-day supply, or 14-day supply for topical corticosteroids.
Empaveli
For C3G or primary IC-MPGN, use maximally tolerated ACE inhibitor, ARB, or SGLT2 inhibitor therapy for at least 12 weeks before initiation and continue it during treatment.
Enbrel — rheumatoid arthritis or PJIA
Use applicable conventional DMARD therapy before Enbrel. RA requires a 3-month trial; PJIA requires a 6-week trial, unless contraindicated or not tolerated.
Enbrel — plaque psoriasis
Trial and failure, contraindication, or intolerance to one topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor. The trial is at least 30 days, or 14 days for topical corticosteroids.
Enbrel — ankylosing spondylitis
Trial and failure, contraindication, or intolerance to one NSAID at maximally tolerated doses for at least 1 month.
Eucrisa
Trial and failure, contraindication, or intolerance to one prescription-strength topical corticosteroid is required unless the affected area is sensitive, including the face, axillae, or groin.
Drug
Step-therapy requirement
Fotivda
Use of a prerequisite Part D drug is required before Fotivda.
Fruzaqla
Use of a prerequisite Part D drug is required before Fruzaqla.
Gilotrif
Use of a prerequisite Part D drug is required before Gilotrif.
Glycopyrrolate
Use concomitant PPI therapy; if a PPI is contraindicated or not tolerated, use concomitant H2-receptor antagonist therapy.
Humira
Try the applicable conventional or topical therapy before Humira, including methotrexate, leflunomide, sulfasalazine, NSAIDs, corticosteroids, vitamin D analogs, tazarotene, or calcineurin inhibitors, depending on the indication. Failure, contraindication, or intolerance is required.
Hyrnuo
Prior systemic therapy, such as chemotherapy, is required before authorization.
Igalmi
Use or attempt at least two acute-agitation products before Igalmi; trial and failure, contraindication, or intolerance is required.
Imbruvica
For the cGVHD indication, use or fail one or more lines of systemic therapy before Imbruvica.
Inbrija — initial therapy
Use or attempt two of the following Parkinson disease medication classes before initial Inbrija: an MAO-B inhibitor, dopamine agonist, or COMT inhibitor. Trial and failure, contraindication, or intolerance is required.
Inbrija — specified classes
Two agents or classes must be tried from an MAO-B inhibitor, dopamine agonist, or COMT inhibitor before Inbrija.
Itraconazole
For fingernail or toenail onychomycosis, oral terbinafine is required before itraconazole, with trial and failure, contraindication, or intolerance. The minimum supply is 6 weeks for fingernail disease and at least 12 weeks for toenail disease.
Authorization Durations and Quantity Limits
Authorization duration rather than quantity limits
Applicable productsCoverage is authorized by duration rather than a quantity limit; product-specific initial and reauthorization rules apply
AdministrationIntramuscular immune globulin at the minimum effective dose and appropriate frequency for the prescribed diagnosis
Immunization requirementThe patient must require immunization
Iclusig
Iclusig chemotherapy-cycle limitUp to 20 cycles when used in combination with chemotherapy for Ph-positive ALL
Covered diagnosesChronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
ContinuationContinuation of prior therapy is approved
Site-of-Care Requirements
Billing Rule
Administer the first Cablivi dose in the office
Arrange for the first Cablivi dose to be administered by a healthcare provider as a bolus intravenous injection. Document the aTTP diagnosis, administration, immunosuppressive therapy, and applicable plasma-exchange status with the authorization request.
The first dose must be administered by a healthcare provider.
Use is with immunosuppressive therapy and either ongoing plasma exchange or completed plasma exchange with fewer than 59 days elapsed.
Prescribing must be by or in consultation with a hematologist or oncologist.
Definitions and Abbreviations
Definitions and abbreviations
CGDChronic granulomatous disease
SMOSevere malignant osteopetrosis
PAH and CTEPHPAH means pulmonary arterial hypertension; CTEPH means chronic thromboembolic pulmonary hypertension
SEGA associated with TSCSubependymal giant cell astrocytoma associated with tuberous sclerosis complex
AAT deficiencyAlpha-1 antitrypsin deficiency; the policy uses a pretreatment serum AAT threshold of < 11 µM/L
MAC lung diseaseMycobacterium avium complex lung disease requiring combination antibacterial therapy and inadequate sputum-culture response after multidrug background treatment
High-risk polycythemia veraAge 60 years or older and/or a prior thrombosis history
Clinical Thresholds and Coding Reference
Measurable clinical values
Transfusional iron overload ferritinMore than 1,000 mcg/L
Eosinophilic esophagitis>= 15 intraepithelial eosinophils per high-power field
Qualifying opioid toleranceAt least 1 week of a qualifying regimen, such as morphine >=60 mg/day, fentanyl transdermal >=25 mcg/hour, or oxycodone >=30 mg/day
Policy Summary
PayerBlue Cross Blue Shield - South Carolina
PolicyACTIMMUNE (S) Prior Authorization Criteria
Policy CodePolicy N/A
Change TypeNo material change
Effective DateOct 1, 2026
Next Review DateN/A
Key ActionSubmit documentation confirming chronic granulomatous disease or severe malignant osteopetrosis.
Progressive, well-differentiated, nonfunctional GI or lung neuroendocrine tumor that is unresectable, locally advanced, or metastatic.
Afinitor Disperz indications
SEGA associated with TSC requiring therapeutic intervention; age at least 1 year.
TSC-associated partial-onset seizures; age at least 2 years.
Avmapki Fakzynja Co-pack: KRAS mutation detected by an FDA-approved or CLIA-approved test and prior systemic therapy.
Avtozma
Moderately to severely active RA with failure, contraindication, or intolerance to two specified agents, or attestation that a trial may be inappropriate.
GCA diagnosis.
Active SJIA with at least a 1-month maximally tolerated NSAID trial.>= 1 month
Active PJIA with failure, contraindication, or intolerance to two specified agents, or attestation that a trial may be inappropriate.
SSc-ILD documented by exclusion of other known ILD causes and qualifying HRCT, with lung-biopsy findings when biopsy was performed.
Ayvakit
Unresectable or metastatic GIST with a PDGFRA exon 18 mutation, including D842V.
AdvSM with platelet count at least 50 x 10^9/L.>= 50 x 10^9/L
ISM with platelet count at least 50 x 10^9/L.>= 50 x 10^9/L
Bosulif: Philadelphia chromosome-positive CML.
Braftovi
Unresectable or metastatic BRAF V600E/V600K-mutant melanoma used with Mektovi.
Unresectable, advanced, or metastatic BRAF V600E-mutant colon or rectal cancer used with Erbitux and prior therapy or fluorouracil-based chemotherapy.
Metastatic BRAF V600E-mutant NSCLC used with Mektovi.
Briviact: Partial-onset seizures and age at least 1 month.>= 1 month
Bronchitol: Cystic fibrosis and a passed Bronchitol Tolerance Test.
Initial prescribing is by or in consultation with a pulmonologist or specialist.
Brukinsa
MCL with at least one prior therapy.
WM/LPL.
Relapsed or refractory MZL with at least one prior anti-CD20-based regimen.
CLL/SLL with contraindication or intolerance to Calquence.
Relapsed or refractory FL used with Gazyva after at least two prior systemic therapy lines.
Brukinsa
MCL after at least one prior therapy.
WM/LPL.
Relapsed or refractory MZL after at least one prior anti-CD20 regimen.
CLL/SLL with Calquence contraindication or intolerance.
Relapsed/refractory FL with Gazyva after at least two prior systemic lines.
Calquence
Previously untreated MCL ineligible for autologous HSCT and used with bendamustine and rituximab.
MCL after at least one prior therapy.
CLL or SLL.
Caplyta
Schizophrenia after failure, contraindication, or intolerance to two listed generic atypical antipsychotics.
Bipolar I or II depressive episodes, as monotherapy or with lithium/valproate, after quetiapine or olanzapine failure, contraindication, or intolerance.
Adjunctive MDD treatment with an antidepressant after aripiprazole and quetiapine failure, contraindication, or intolerance.
Caprelsa: Metastatic or unresectable locally advanced MTC with symptomatic or progressive disease.
Cayston: Pseudomonas aeruginosa in the lungs; for reauthorization, documented benefit such as fewer pulmonary exacerbations; initial age at least 7 years.
Cerdelga: Type 1 Gaucher disease; CYP2D6 extensive, intermediate, or poor metabolizer status confirmed by an FDA-cleared test; age at least 18 years.
Cholbam
Bile acid synthesis disorder due to a single enzyme defect confirmed by urinary bile acid analysis or molecular genetic testing.
Peroxisomal disorder confirmed by testing, with liver disease, steatorrhea, or fat-soluble-vitamin complications, and used adjunctively.
Cometriq: Metastatic medullary thyroid cancer.
Copiktra: Relapsed or refractory CLL/SLL and trial and failure, contraindication, or intolerance to at least two prior therapies.>= 2 prior therapies
Cosentyx
Plaque psoriasis meeting severity criteria and topical-therapy trial.
Active PsA with qualifying joint, skin, nail, axial, dactylitis, or enthesitis findings.
Active AS with a 1-month NSAID trial.
Active nr-axSpA or ERA with objective inflammation and 1-month trials of two NSAIDs.
Moderate-to-severe HS.
Continuation response
Requested product was previously authorized and continuation is documented.
Where required, positive clinical response from baseline is documented.
Transfusional iron overload with ferritin over 1,000 mcg/L and at least 100 mL/kg packed RBC transfusions.
MDS with low or Intermediate-1 disease or potential transplant status and more than 20 RBC transfusions.
NTDT with liver iron concentration at least 5 mg Fe/g dw.
Metyrosine
Biochemically confirmed pheochromocytoma for preoperative preparation after alpha- and beta-blocker failure, contraindication, or intolerance.
Hormonally active or malignant pheochromocytoma when surgery is unsuitable or chronic treatment is needed and normotension is not achieved after alpha-1 and beta blockade.
Diacomit: Dravet syndrome-associated seizures; clobazam combination; weight at least 7 kg; age at least 6 months.
Chronic, relapsed/refractory, or pediatric persistent ITP; platelet count below 30,000/mcL; and prior therapy failure, contraindication, or intolerance.
Dulera: Breo Ellipta prerequisite is satisfied or an exception applies; for asthma reauthorization, positive clinical response is documented.
Bullous pemphigoid, CSU, AFRS, or prurigo nodularis meeting the applicable disease criteria.
Ebglyss: Age at least 12 years, weight at least 40 kg, moderate-to-severe atopic dermatitis with at least 10% BSA or SCORAD at least 25, and required topical corticosteroid trial, contraindication, or intolerance.
Emgality
Episodic migraine with at least 4 migraine days/month using 120 mg/mL.
Chronic migraine with at least 8 migraine days/month using 120 mg/mL and medication-overuse headache addressed.
Episodic cluster headache with at least two qualifying cluster periods using 100 mg/mL.
Empaveli
PNH.
C3G or primary IC-MPGN used to reduce proteinuria; age at least 12 years; required ACE inhibitor, ARB, or SGLT2 inhibitor therapy for at least 12 weeks; and no kidney transplant for primary IC-MPGN.
Enbrel
RA with at least a 3-month conventional DMARD trial.
PJIA with at least a 6-week conventional DMARD trial.
Active PsA with qualifying findings.
Plaque psoriasis meeting severity and topical-treatment criteria.
Active AS with at least a 1-month NSAID trial.
Reauthorization: Positive clinical response from baseline is documented using the indication-appropriate disease, symptom, laboratory, functional, BSA, joint-count, or axial-status measure.
Fabry disease established by GLA mutation, alpha-galactosidase A deficiency, or significant clinical manifestations; age at least 2 years.
Fentanyl citrate oral transmucosal: Breakthrough cancer pain; around-the-clock long-acting opioid; at least one week of qualifying opioid tolerance; and pain, oncology, hematology, hospice, or palliative-care specialist involvement.
Fintepla: Seizures associated with Dravet or Lennox-Gastaut syndrome; age at least 2 years; neurologist involvement.
Icatibant: Confirmed HAE by the applicable laboratory or genetic/family-history pathway; acute-attack use; age at least 18 years; specialist involvement; and no combination with another acute HAE treatment.
Firmagon: Advanced or metastatic prostate cancer.
Fotivda: Advanced relapsed or refractory renal cell carcinoma after at least two prior systemic therapies.>= 2 prior systemic therapies
Fruzaqla: Metastatic colorectal cancer after fluoropyrimidine-, oxaliplatin-, irinotecan-, and anti-VEGF therapy, with the applicable RAS-dependent pathway.
Gamastan: Intramuscular immune globulin at the minimum effective dose and appropriate frequency for a patient requiring immunization.
Gavreto
RET fusion-positive NSCLC confirmed by FDA-approved or CLIA-approved testing.
Advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and radioactive iodine-refractory or inappropriate disease; age at least 12 years.
Fingolimod or glatiramer acetate: Relapsing MS with neurologist prescribing or consultation; for reauthorization, positive response; no combination with another MS disease-modifying therapy.
Gilotrif: Advanced or metastatic stage IIIB/IV NSCLC with the qualifying EGFR first-line or post-platinum treatment pathway.
Imatinib
Ph+/BCR-ABL-positive CML or ALL.
GIST.
Unresectable, recurrent, or metastatic dermatofibrosarcoma protuberans.
Hypereosinophilic syndrome, chronic eosinophilic leukemia, MDS, or myeloproliferative disease.
Glycopyrrolate: Peptic ulcer with concomitant PPI, or PPI contraindication/intolerance plus H2-receptor antagonist; reauthorization requires unhealed/new ulcer, continued acid suppression, and reduced symptoms.
Gomekli: Neurofibromatosis type 1 with inoperable plexiform neurofibromas.
Preferred growth hormone
One covered pediatric or adult growth-hormone indication meeting diagnosis-specific growth, laboratory, genetic, renal, or stimulation-test criteria.
Required endocrinology or nephrology involvement and monitoring documentation.
Hernexeos: Unresectable or metastatic non-squamous NSCLC with an activating HER2 mutation confirmed by FDA-approved or approved-facility testing.
Humira
One covered indication: RA, PJIA, PsA, plaque psoriasis, AS, CD, uveitis, UC, or HS, meeting indication-specific severity and prerequisite-treatment criteria.
For reauthorization, positive clinical response appropriate to the indication is documented.
Hyrnuo: Locally advanced or metastatic non-squamous NSCLC with an activating HER2 mutation and prior systemic therapy.
Inbrija: Parkinson disease with intermittent OFF episodes, current carbidopa/levodopa treatment, and failure, contraindication, or intolerance to two of an MAO-B inhibitor, dopamine agonist, or COMT inhibitor; neurologist involvement.
Increlex
Severe primary IGF-1 deficiency with height SDS at or below -3.0, basal IGF-1 SDS at or below -3.0, and normal or elevated GH.
GH gene deletion with developed neutralizing antibodies.
Inluriyo: Advanced or metastatic ER-positive, HER2-negative breast cancer with ESR1 mutation and progression after at least one line of endocrine therapy.
Inlyta
First-line treatment with avelumab or pembrolizumab.
Treatment after failure of one prior systemic therapy such as chemotherapy.
Inqovi
MDS or CMML with intermediate-1, intermediate-2, or high-risk IPSS.
Newly diagnosed AML used with venetoclax and age at least 75 years or comorbidities precluding intensive induction.
Inrebic
Primary myelofibrosis.
Post-polycythemia vera myelofibrosis.
Post-essential thrombocythemia myelofibrosis.
Gefitinib: Metastatic NSCLC with active EGFR exon 19 deletion or exon 21 L858R mutation confirmed by FDA-approved or CLIA-approved testing.
Isturisa: Cushing syndrome with endogenous hypercortisolemia when surgery is unsuitable or noncurative; endocrinologist involvement.
Itovebi: Locally advanced or metastatic PIK3CA-mutated, HR-positive, HER2-negative breast cancer after adjuvant endocrine therapy and used with Ibrance.
Itraconazole
Systemic fungal infection.
Confirmed fingernail onychomycosis and oral terbinafine trial/failure, contraindication, or intolerance.
Confirmed toenail onychomycosis and oral terbinafine trial/failure, contraindication, or intolerance.
Besremi: Polycythemia vera with qualifying blood count, JAK2 or erythropoietin finding, and prerequisite therapy for high-risk disease.
Bosulif: Philadelphia chromosome-positive CML.
Braftovi
Qualifying BRAF-mutant melanoma with Mektovi.
Qualifying BRAF-mutant colorectal cancer with Erbitux and required prior therapy or chemotherapy.
BRAF V600E-mutant metastatic NSCLC with Mektovi.
Briviact: Partial-onset seizures and age at least 1 month.
Bronchitol: Cystic fibrosis and passed Bronchitol Tolerance Test.
Brukinsa
MCL after at least one prior therapy.
WM/LPL.
Relapsed/refractory MZL after anti-CD20 therapy.
CLL/SLL with Calquence contraindication or intolerance.
Relapsed/refractory FL with Gazyva after at least two systemic lines.
MCL with qualifying untreated or previously treated pathway.
CLL/SLL.
Caplyta
Schizophrenia after two generic atypical-antipsychotic trials or exceptions.
Bipolar depression after quetiapine or olanzapine trial or exception.
Adjunctive MDD after aripiprazole and quetiapine trial or exception.
Caprelsa: Metastatic or unresectable locally advanced symptomatic or progressive MTC.
Cayston: Pulmonary Pseudomonas aeruginosa and age at least 7 years.
Cerdelga: Type 1 Gaucher disease, eligible CYP2D6 metabolizer status by FDA-cleared test, and age at least 18 years.
Cholbam
Bile acid synthesis disorder due to a single enzyme defect confirmed by testing.
Peroxisomal disorder confirmed by testing with qualifying manifestations and adjunctive use.
Tadalafil: No concurrent nitrate use and alpha-blocker or 5-alpha reductase inhibitor contraindication or intolerance.
Ciclopirox: Confirmed fingernail or toenail onychomycosis without lunula involvement, qualifying severity, and required terbinafine trial or exception.
Cinryze: Age at least 6 years; qualifying HAE; prophylaxis indication; specialist involvement; and no combination prophylaxis.
Cobenfy: Intolerance to two oral generic formulary atypical antipsychotics.
Cometriq: Metastatic MTC and continuation of prior therapy.
Copiktra: Relapsed/refractory CLL/SLL after at least two prior therapies.
Cosentyx
Plaque psoriasis meeting severity and topical-treatment criteria.
PsA, AS, nr-axSpA, ERA, or HS meeting diagnosis-specific criteria.
MDS meeting risk and transfusion criteria.
NTDT with LIC at least 5 mg Fe/g dw.
Metyrosine
Biochemically confirmed pheochromocytoma for preoperative preparation after alpha- and beta-blocker trial or exception.
Qualifying hormonally active or malignant pheochromocytoma when surgery is unsuitable or noncurative and normotension is not achieved after blockade.
Diacomit: Dravet syndrome-associated seizures, clobazam combination, weight at least 7 kg, and age at least 6 months.
Doptelet
TPPP with chronic liver disease, planned procedure, and platelets below 50,000/mcL.
Qualifying ITP with platelets below 30,000/mcL and prior therapy failure or exception.
Ebglyss: Age at least 12 years, weight at least 40 kg, moderate-to-severe AD with at least 10% BSA or SCORAD at least 25, and topical-treatment trial or exception.
Emgality
Episodic migraine with at least 4 migraine days/month using 120 mg/mL.
Chronic migraine with at least 8 migraine days/month using 120 mg/mL.
Episodic cluster headache with qualifying cluster periods using 100 mg/mL.
Empaveli
PNH.
C3G or primary IC-MPGN meeting age, transplant, proteinuria, and background-therapy criteria.
Enbrel
RA, PJIA, PsA, plaque psoriasis, or AS meeting diagnosis, severity, prerequisite, and specialist criteria.
Fabrazyme: Fabry disease established by GLA mutation, alpha-galactosidase A deficiency, or significant manifestations; age at least 2 years.
Fentanyl: Breakthrough cancer pain, around-the-clock long-acting opioid, at least one week of qualifying opioid tolerance, and approved specialist involvement.
Fintepla: Dravet or Lennox-Gastaut syndrome-associated seizures; age at least 2 years; neurologist involvement.
Icatibant: Confirmed HAE, acute-attack use, age at least 18 years, specialist involvement, and no combination with another acute HAE treatment.
Firmagon: Advanced or metastatic prostate cancer.
Fotivda: Advanced relapsed or refractory RCC after at least two prior systemic therapies.
Fruzaqla: Metastatic colorectal cancer after required chemotherapy and biologic therapy pathways.
Gamastan: Intramuscular immune globulin at the minimum effective dose and appropriate frequency for a patient requiring immunization.
Gavreto
RET fusion-positive NSCLC.
Advanced/metastatic RET fusion-positive thyroid cancer requiring systemic therapy and radioactive iodine-refractory or inappropriate disease; age at least 12 years.
Fingolimod, Gilotrif, or glatiramer acetate: Meet the product-specific relapsing-MS or EGFR-mutated NSCLC pathway, including required neurologist involvement or prior therapy.
Imatinib
Ph+/BCR-ABL-positive CML or ALL.
GIST, qualifying DFSP, HES/CEL, MDS, or myeloproliferative disease.
Glycopyrrolate: Peptic ulcer with PPI therapy, or PPI contraindication/intolerance plus H2-receptor antagonist therapy.
Gomekli: NF1 with inoperable plexiform neurofibromas.
Preferred growth hormone
One covered growth-hormone diagnosis meeting the applicable growth, stature, laboratory, genetic, renal, or stimulation-test criteria.
Required endocrinology or nephrology involvement.
Severe primary IGF-1 deficiency with height and basal IGF-1 SDS at or below -3.0 and normal/elevated GH.
GH gene deletion with neutralizing antibodies.
Inluriyo: Advanced/metastatic ER-positive, HER2-negative breast cancer with ESR1 mutation and progression after endocrine therapy.
Inlyta
First-line with avelumab or pembrolizumab.
After failure of one prior systemic therapy.
Inqovi
MDS/CMML with intermediate-1, intermediate-2, or high-risk IPSS.
Newly diagnosed AML with venetoclax and age at least 75 years or qualifying comorbidities.
Inrebic
Primary myelofibrosis.
Post-polycythemia vera myelofibrosis.
Post-essential thrombocythemia myelofibrosis.
Gefitinib: Metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation confirmed by approved testing.
Isturisa: Cushing syndrome with endogenous hypercortisolemia when surgery is unsuitable or noncurative; endocrinologist involvement.
Itovebi: Locally advanced/metastatic PIK3CA-mutated, HR-positive, HER2-negative breast cancer after adjuvant endocrine therapy and used with Ibrance.
Itraconazole
Systemic fungal infection.
Confirmed fingernail or toenail onychomycosis with oral terbinafine failure, contraindication, or intolerance.
Cholbam: Positive clinical response is documented by improved liver function.
Positive clinical response is documented.
Enbrel:
Positive clinical response from baseline is documented using the indication-appropriate joint, symptom, BSA, laboratory, functional, axial-status, or disease-activity measure.
Positive clinical response and no combination with another approved acute HAE treatment.
Humira: Positive clinical response appropriate to the requested indication is documented.
Inbrija: Positive clinical response is documented.
Increlex: Positive clinical response is documented.
Isturisa: Positive clinical response is documented.
Itovebi or Inluriyo: Continuation of prior therapy is documented.